Genetics, Genomics & Molecular Diagnostics News

The agency expects existing programs to guide its regulation, adding that modified portions of animal genomes would be considered drugs.

In addition to variant detection technology, Omicia also gets technologies like data compression, which will aid diagnostics development and data storage. 

Through the deal, Ginkgo has picked up Gen9's manufacturing platform and suite of proprietary technologies, software, and informatics tools for DNA synthesis and assembly.

The researchers used both targeted and exome sequencing to genetically diagnose patients.

CareDx's CareDx Pty subsidiary said it will pay up to $735,000 to Conexio as a percentage of revenues from products acquired in the deal. 

The Houston- and Slovenia-based data firm wants to boot scientists off Excel spreadsheets and onto its flexible, proprietary platform for data management.

CareDx's CareDx Pty subsidiary said it will pay up to $735,000 to Conexio as a percentage of revenues from products acquired in the deal. 

Investigators uncovered 33 hotspots of large tandem duplications among breast cancer cases that affected cancer susceptibility genes and super-enhancers.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.

Genotoxicity workflows performed manually are subject to workflow bottlenecks, where the throughput is inherently limited, and active time spent performing the tests reduces the lab’s overall efficiency. Additionally, variability associated with operator technique and laboratory conditions could lead to a loss in precision, or worse, systematic errors that can skew results. This article demonstrates automated imaging as it pertains to the comet and gamma-H2AX assays in order to simplify genotoxicity assay workflows and provide robust results.

Stringent guidelines of quality assurance and control (QA/QC) serve as the foundation for dependable and reproducible results in any analytical endeavor. Here we highlight step-by-step, the measures implemented by Myriad RBM that take Luminex xMAP technology to a high level of reproducibility and ruggedness. The Myriad RBM platform combines the sensitivity and dynamic range of microsphere-based immuno-multiplexing with the precision and dependability of automated liquid handling.

Single cell analysis has become increasingly important in translational research allowing scientist to study cell-to-cell variations within a cell population. However, the current flow cytometry protocols are limited to 16-20 protein biomarkers and samples are stable for only 1-5 days. In this White Paper we present an overview on assays, instrumentation and applications of the high parameter ChipCytometry platform and the ability to store clinical samples for a period of 24 months at full biomarker integrity.